Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thrombocytopenia
Pharma
Argenx's Vyvgart comes up short of placebo in ITP trial
Argenx's Vyvgart Hytrulo has flunked primary and secondary endpoints in a phase 3 study in a rare bleeding disorder, primary immune thrombocytopenia.
Kevin Dunleavy
Nov 28, 2023 11:20am
In $1.7B buy, Sobi acquires CTI and myelofibrosis drug Vonjo
May 10, 2023 11:25am
FDA limits the use of the J&J vax because of blood clot threat
May 6, 2022 9:12am